Closed Research Trials

PRISMS, or A Phase IIIb, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients with Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits is a study sponsored by Genentech, Inc., which is being conducted in the TTUHSC El Paso Department of Neurology.

Alteplase has been previously approved by the FDA for use in patients who have had moderate or severe strokes. This study will test the investigational use of the drug alteplase to determine if the use of the drug leads to an overall better outcome in individuals who have had mild strokes.

This study is expected to be ongoing for the next four years.

The PI for this study is Salvador Cruz-Flores, M.D., and co-investigators are Alberto Maud, M.D., Gustavo J. Rodriguez, M.D., and Paisith Piriyawat, M.D.

For more information about this clinical trial please call study coordinator Israel Alba at 915-215-4616.

SOCRATES is the descriptor for the study Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor Compared to Aspirin and Patient Outcomes: A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events with Ticagrelor Compared to Aspirin (ASA) in Patients with Acute Ischaemic Stroke or TIA which is being conducted in the TTUHSC El Paso Department of Neurology.

The study is being funded by AstraZeneca Pharmaceuticals and enrollment is planned for the next three years.

The objective of this pharmaceutical trial is to compare the efficacy of the study compound ticagrelor to aspirin in the treatment of an acute ischaemic or a transient ischaemic attack. Ticagrelor, or Brilinta, is a blood-thinning drug approved by the FDA used to reduce cardiovascular death and heart in patients with acute coronary syndromes.

The PI is Salvador Cruz-Flores, M.D., and co-investigators include Paisith Piriyawat, M.D., Alberto Maud, M.D., and Gustavo J. Rodriguez, M.D.

For more information about this clinical trial please call the study coordinator Israel Alba at 915-215-4616.

 

ATACH-II is the acronym for the Antihypertensive Treatment of Acute Cerebral Hemorrhage: A Phase III Randomized Multicenter Clinical Trial of Blood Pressure Reduction for Hypertension in Acute Intracerebral Hemorrhage currently being conducted in the TTUHSC El Paso Department of Neurology. ATACH-II is funded by NINDS and NIH, with a planned enrollment period of four years and a planned duration of the study over a period of five years.

The primary objective of this study is to determine the therapeutic benefit of intensive systolic blood pressure (SPB < 140 mmHg) compared with standard systolic blood pressure (SBP < 180 mmHg) in reducing the number of patients with death and disability at day ninety among subjects with intracerebral hemorrhage treated within 4.50 hours of symptom onset.

The study hypothesis proposes that intensive systolic blood pressure reduction using intravenous nicardipine with treatment initiated within the 4.50 hours of ICH onset, and continued for the next 24 hours, will reduce the outcome of death or disability among these patients.

The PI of this trial is Gustavo J. Rodriguez, M.D., and co-investigators include Alberto Maud, M.D., Salvador Cruz-Flores, M.D., and Paisith Piriyawat, M.D.

For additional information regarding this project please contact the study coordinator with the department of neurology, Israel Alba at 915-215-4616.